In the era of targeted therapy based on genomic alterations, the treatment strategy for
metastatic colorectal cancer (mCRC) has been changing. Before systemic treatment …

Remarkable progress has been made in the development of biomarker-driven targeted
therapies for patients with multiple cancer types, including melanoma, breast and lung …

Background HER2 amplification has been identified in 2–3% of patients with colorectal
cancer, although there are currently no approved HER2-targeted therapies for colorectal …

Background HER2 is an actionable target in metastatic colorectal cancer. We assessed the
activity of tucatinib plus trastuzumab in patients with chemotherapy-refractory, HER2 …

Abstract DESTINY-CRC01 (NCT03384940) was a multicenter, open-label, phase 2 trial
assessing the efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients with HER2 …

Human epidermal growth factor receptor 2 (HER2) is a well-known oncogenic driver in
different tumors and an approved therapeutic target in breast and gastroesophageal cancer …

Importance Amplification ofERBB2 (formerly referred to asHER2) is present in nearly 3% of
patients with metastatic colorectal cancer overall and 5% of patients …

Despite recent advances in the treatment of metastatic colorectal cancer (mCRC), 5 years
survival rates remain low. Chemotherapy remains as the mainstay of treatment with only few …

Colorectal cancer (CRC) is the second most lethal cancer worldwide and the prognosis of
metastatic CRC (mCRC) remains poor. Recent advancements in translational research have …

In the era of precision medicine, it has been increasingly recognized that individuals with a
certain disease are complex and different from each other. Due to the underestimation of the …